120 related articles for article (PubMed ID: 11465726)
1. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).
D'Arcy CA; Mannik M
Arthritis Rheum; 2001 Jul; 44(7):1717-8. PubMed ID: 11465726
[No Abstract] [Full Text] [Related]
2. Serum sickness following treatment with rituximab.
Todd DJ; Helfgott SM
J Rheumatol; 2007 Feb; 34(2):430-3. PubMed ID: 17295433
[TBL] [Abstract][Full Text] [Related]
3. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-induced serum sickness.
Schutgens RE
Br J Haematol; 2006 Oct; 135(2):147. PubMed ID: 16869826
[No Abstract] [Full Text] [Related]
5. Rituximab-induced serum sickness.
Herishanu Y
Am J Hematol; 2002 Aug; 70(4):329. PubMed ID: 12214584
[No Abstract] [Full Text] [Related]
6. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
7. Transfusion Medicine Illustrated. Monoclonal antibody-stimulated serum sickness.
Proctor L; Renzulli B; Warren S; Brecher ME
Transfusion; 2004 Jul; 44(7):955. PubMed ID: 15225231
[No Abstract] [Full Text] [Related]
8. Serum sickness due to infliximab in a patient with psoriasis.
Krishnan RS; Hsu S
J Drugs Dermatol; 2004; 3(3):305-8. PubMed ID: 15176166
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.
Kunzmann V; Ruediger T; Hallek M; Mueller-Hermelink HK; Wilhelm M
Blood; 2001 Sep; 98(6):1991-2. PubMed ID: 11565541
[No Abstract] [Full Text] [Related]
10. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
11. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
Quartier P; Tournilhac O; Archimbaud C; Lazaro L; Chaleteix C; Millet P; Peigue-Lafeuille H; Blanche S; Fischer A; Casanova JL; Travade P; Tardieu M
Clin Infect Dis; 2003 Feb; 36(3):e47-9. PubMed ID: 12539090
[TBL] [Abstract][Full Text] [Related]
12. Serum sickness-like reactions in patients receiving intravenous infliximab.
Gamarra RM; McGraw SD; Drelichman VS; Maas LC
J Emerg Med; 2006 Jan; 30(1):41-4. PubMed ID: 16434333
[TBL] [Abstract][Full Text] [Related]
13. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature.
Seifert G; Reindl T; Lobitz S; Seeger K; Henze G
Haematologica; 2006 Jun; 91(6 Suppl):ECR23. PubMed ID: 16785126
[TBL] [Abstract][Full Text] [Related]
14. Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies.
Killestein J; Jasperse B; Liedorp M; Seewann A; Polman Ch
Mult Scler; 2009 Apr; 15(4):525-6. PubMed ID: 19324985
[No Abstract] [Full Text] [Related]
15. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.
Finger E; Scheinberg M
J Clin Rheumatol; 2007 Apr; 13(2):94-5. PubMed ID: 17414540
[TBL] [Abstract][Full Text] [Related]
16. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.
Hellerstedt B; Ahmed A
Ann Oncol; 2003 Dec; 14(12):1792. PubMed ID: 14630688
[No Abstract] [Full Text] [Related]
17. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia.
Catuogno M; Rezai S; Priori R; Magrini L; Valesini G
Rheumatology (Oxford); 2005 Mar; 44(3):406. PubMed ID: 15637037
[No Abstract] [Full Text] [Related]
18. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus.
Saito K; Nawata M; Iwata S; Tokunaga M; Tanaka Y
Rheumatology (Oxford); 2005 Nov; 44(11):1462-4. PubMed ID: 16105908
[No Abstract] [Full Text] [Related]
19. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
20. Serum sickness following a first rituximab infusion with no recurrence after the second one.
Mehsen N; Yvon CM; Richez C; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(5):967. PubMed ID: 19032839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
